JOHN KIRKWOOD to Recurrence
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Recurrence.
Connection Strength
0.083
-
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res. 2010 Feb 01; 16(3):1042-8.
Score: 0.047
-
Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006 Feb 16; 354(7):709-18.
Score: 0.036